Cardiome Pharma Corp. (Nasdaq: CRME) partnered with Merck (MYSE: MRK) to develop an oral version of Cardiome's atrial fibrillation drug vernakalant. Merck will pay up to $600 million to Cardiome to market the heart treatment. Shares of Cardiome soared 79 cents to close at $3.97 while Merck stock eased 46 cents to close at $26.30.
Cardiome Partners With Merck
April 09, 2009 at 17:14 PM EDT
